Boston, Massachusetts 02215


Purpose:

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.


Study summary:

PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of congestive heart failure (CHF) in patients from the clinical trial ECOG-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.


Criteria:

Inclusion Criteria: - European American patients with DNA available - European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab - African American cases (based on a drop in left ventricular ejection fraction [LVEF] < 50 or a drop from baseline > 20 points) and African American controls


NCT ID:

NCT02610426


Primary Contact:

Principal Investigator
Bryan P Schneider
Eastern Cooperative Oncology Group


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Bryan P. Schneider
Phone: 317-274-6473
Email: bpschnei@iupui.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.